Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2023-07-18 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi intends to carry out a rights issue of approximately SEK 6,000 million and calls for an Extraordinary General Meeting to be held on 15 August 2023
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) announcing an upcoming rights issue of approximately SEK 6,000 million and the calling of an Extraordinary General Meeting (EGM) to authorize this capital raise. The document details the purpose of the capital raise (repaying a bridge loan for the acquisition of CTI BioPharma) and mentions shareholder support. Since this is an announcement regarding a capital structure change and a new share issue, it falls under the 'Share Issue/Capital Change' category.
2023-07-18 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för andra kvartalet 2023' (Interim Report for the second quarter of 2023). It contains comprehensive financial statements, including income statements, revenue breakdowns by segment, and management commentary on business performance and outlook. It is clearly a substantive financial report for a period shorter than a full fiscal year, not merely an announcement or certification. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q2 2023
2023-07-18 Swedish
Earnings Release 2023
Earnings Release Classification · 100% confidence The document text contains a CEO statement, financial highlights for 'Q2 2023 report', detailed tables comparing Q2 2023 results with Q2 2022, updated outlooks, and extensive financial performance breakdowns for the second quarter and first half of the year. The content is a comprehensive review of periodic financial results, including revenue, EBITA, EPS, and management commentary. This structure is characteristic of an Interim/Quarterly Report (IR), which provides detailed financial statements for a period shorter than a year. It is too detailed to be just an Earnings Release (ER) and clearly covers a period shorter than a full fiscal year, ruling out a 10-K. It is not a mere announcement of a report (RPA) as the full content is present. Q2 2023
2023-07-18 English
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states the 'New number of shares and votes' as of a specific date (30 June 2023), detailing an increase due to the issuance and subsequent conversion of class C shares into common shares. It also mentions the total number of shares held by the company. This content directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is short and appears to be a direct regulatory disclosure, not an announcement of a larger report.
2023-06-30 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement in Swedish regarding a change in the total number of shares and votes for Swedish Orphan Biovitrum AB (Sobi) as of June 30, 2023. It specifically mentions the issuance of C-shares that were converted to common stock to secure commitments under a long-term incentive program for management. This directly relates to a change in the company's capital structure (share count). This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The final sentence confirms it is information Sobi is obliged to disclose under financial instrument trading laws, suggesting a regulatory filing, but the content is specifically about share count change, making SHA the most precise fit.
2023-06-30 Swedish
Sobi har framgångsrikt slutfört uppköpserbjudandet avseende samtliga utestående stamaktier i CTI BioPharma Corp.
M&A Activity Classification · 99% confidence The document is a press release written in Swedish announcing the successful completion of a tender offer (uppköpserbjudande) by Sobi to acquire all outstanding shares of CTI BioPharma Corp. It details the acceptance rate (83.8%), the final steps (merger expected on June 26, 2023), and mentions filing a Schedule TO with the SEC. This document is an announcement regarding a significant corporate transaction, specifically a takeover/merger activity, which aligns with the definition of M&A Activity (TAR). It is not the final regulatory filing itself, but the announcement of the transaction's conclusion.
2023-06-24 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.